Lifeboat Foundation

Any device that sends out a Wi-Fi signal also emits terahertz waves —electromagnetic waves with a frequency somewhere between microwaves and infrared light. These high-frequency radiation waves, known as “T-rays,” are also produced by almost anything that registers a temperature, including our own bodies and the inanimate objects around us.

Terahertz waves are pervasive in our daily lives, and if harnessed, their concentrated power could potentially serve as an alternate energy source. Imagine, for instance, a cellphone add-on that passively soaks up ambient T-rays and uses their energy to charge your phone. However, to date, terahertz waves are wasted energy, as there has been no practical way to capture and convert them into any usable form.

Now physicists at MIT have come up with a blueprint for a device they believe would be able to convert ambient terahertz waves into a direct current, a form of electricity that powers many household electronics.

An international team with the participation of Prof. Dr. Michael Kues from the Cluster of Excellence PhoenixD at Leibniz University Hannover has developed a new method for generating quantum-entangled photons in a spectral range of light that was previously inaccessible. The discovery can make the encryption of satellite-based communications much more secure in the future.

A 15-member research team from the U.K., Germany and Japan has developed a new method for generating and detecting quantum-entangled photons at a wavelength of 2.1 micrometers. In practice, entangled photons are used in encryption methods such as quantum key distribution to completely secure telecommunications between two partners against eavesdropping attempts. The research results are presented to the public for the first time in the current issue of Science Advances.

It has been regarded as technically possible to implement encryption mechanisms with entangled photons in the near-infrared range of 700 to 1550 nanometers. However, these shorter wavelengths have disadvantages, especially in satellite-based communication. They are disturbed by light-absorbing gases in the atmosphere as well as the background radiation of the sun. With existing technology, end-to-end encryption of transmitted data can only be guaranteed at night, but not on sunny and cloudy days.

Many people are turning to Zoom in this time. I suggested my Dad use it for his church…but…Watch Out! After #coronavirus domains, experts find a massive surge in suspicious “Zoom” named domains in the last 7 days, potentially registered by hackers to exploit #Zoom’s overnight success in this pandemic time to spread #malware… #COVID19

Covid-19 impact: hackers begin exploiting zoom’s overnight success to spread malware during coronavirus outbreak with fake domains and websites.

Circa 2018: In January 2017, while one of us was serving as a homeland security advisor to outgoing President Barack Obama, a deadly pandemic was among the scenarios that the outgoing and incoming U.S. Cabinet officials discussed in a daylong exercise that focused on honing interagency coordination and rapid federal response to potential crises. The exercise is an important element of the preparations during transitions between administrations, and it seemed things were off to a good start with a commitment to continuity and a focus on biodefense, preparedness, and the Global Health Security Agenda—an initiative begun by the Obama administration to help build health security capacity in the most critically at-risk countries around the world and to prevent the spread of infectious disease. But that commitment was short-lived.

Deadly diseases like Ebola and the avian flu are only one flight away. The U.S. government must start taking preparedness seriously.

The zone under international law stretches 200 nautical miles from the Japanese coastline.

It was flying into the Sea of Japan according to Seoul’s Joint Chiefs of Staff.

The US and China have called for Pyongyang to re-enter talks to end its nuclear and missile programmes, according to the Daily Star.

Hospitals brace for coronavirus fight but fears about lack of equipment remain.

Clinicians and mechanical engineers from University College London (UCL) worked with Mercedes to create the continuous positive airway pressure (CPAP) device, which has been approved by the NHS.

The potentially life-saving technology has already been used in China, where coronavirus first emerged in December, and also in hospitals in Italy — the epicentre of the pandemic in Europe. The device helps COVID-19 patients with serious lung infections caused by the disease — such as pneumonia — to breathe more easily, when oxygen alone does not prove sufficient.

Formula One teams are among the British firms joining forces to provide UK hospitals with vital equipment for COVID-19 patients.

Continue reading “Coronavirus: Mercedes helps develop breathing aid as F1 teams join ventilators effort” »

Just like any other virus, the coronavirus needs a host to survive. Viruses enter the cells of the human body to cause disease by attaching to a specific receptor site on the host cell membrane. To do this, they attach to proteins in the capsid through glycoproteins found in the envelope of the virus.

Now, infection biologists form the German Primate Center — Leibniz Institute for Primate Research in Göttingen, together with colleagues at Charité – Universitätsmedizin Berlin, have found how the novel coronavirus SARS-CoV-2 penetrates the cells.

Can intravenous administration of high-dose vitamin C reduce organ failure scores and biomarkers of inflammation and vascular injury among patients with sepsis and acute respiratory distress syndrome (ARDS)?

This randomized clinical trial compares the effects of treatment with intravenous vitamin C, hydrocortisone, and thiamine compared with intravenous hydrocortisone alone on duration of time alive and free of vasopressor use over 7 days in patients with septic shock.

Tomoko Fujii, MD, PhD; Nora Luethi, MD; Paul J. Young, MBChB, PhD; Daniel R. Frei, BSc, MBChB; Glenn M. Eastwood, PhD; Craig J. French, MB, BS; Adam M. Deane, MB, BS, PhD; Yahya Shehabi, MB, BS, PhD; Ludhmila A. Hajjar, MD, PhD; Gisele Oliveira, MD; Andrew A. Udy, MBChB, PhD; Neil Orford, MB, BS, PhD; Samantha J. Edney, BSN; Anna L. Hunt, BN, PGDipHSM, PGDipClinRes; Harriet L. Judd, BSN, PGDipHC; Laurent Bitker, MD; Luca Cioccari, MD; Thummaporn Naorungroj, MD; Fumitaka Yanase, MD; Samantha Bates, BN, PGDipCritCare; Forbes McGain, MB, BS, PhD; Elizabeth P. Hudson, MD; Wisam Al-Bassam, MBChB; Dhiraj Bhatia Dwivedi, BScNsg, MBA; Chloe Peppin, BN, PGDipCritCare; Phoebe McCracken, MPH; Judit Orosz, MD; Michael Bailey, PhD; Rinaldo Bellomo, MD, PhD; for the VITAMINS Trial Investigators.